Skip to Main Content

Jennifer Michlitsch

MD

Pediatric hematologist-oncologist

Dr. Jennifer Michlitsch is a specialist in pediatric blood diseases whose focus is on caring for children with sarcomas, cancerous tumors in bone or other tissues. She has a special interest in treating patients with relapsed sarcomas and other childhood cancers.

Michlitsch's research focuses on new treatments for children with relapsed and treatment-resistant cancers. She has a particular interest in bringing these therapies to all patients at UCSF Benioff Children's Hospital Oakland, regardless of socioeconomic status.

Michlitsch earned her medical degree from the Keck School of Medicine of USC. She completed a residency in pediatrics at Children's Hospital Los Angeles and a fellowship in pediatric hematology and oncology at UCSF Benioff Children's Hospital Oakland.

Michlitsch is a member of the American Society of Pediatric Hematology/Oncology, Children's Oncology Group (COG) and COG's young investigator mentorship program.

  • Education

    Keck School of Medicine of USC, MD, 2001

  • Residencies

    Children's Hospital Los Angeles, Pediatrics, 2014

  • Fellowships

    UCSF, Pediatric Hematology and Oncology, 2009

  • Academic Title

    Professor

Decorative Caduceus

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

To measure the response of treatments chosen based on: • Event free survival (EFS)

Recruiting

More about this study
Decorative Caduceus

Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

To evaluate the efficacy of difluoromethylornithine (DFMO) in combination with etoposide in patients with relapsed/refractory neuroblastoma, based upon: o Event free survival (EFS) from time of enrollment.

Recruiting

More about this study
Decorative Caduceus

Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

Measured by the presence of radiologically assessable disease by cross-sectional computed tomography (CT) or Magnetic resonance imaging (MRI) imaging and/or by metaiodobenzylguanidine (MIBG) or positron emission tomography (PET) s...

Recruiting

More about this study
Decorative Caduceus

Neuroblastoma Maintenance Therapy Trial

Recruiting

More about this study
Decorative Caduceus

Project: Every Child for Younger Patients With Cancer

The number of patients who agree to be in the Biobanking part of the study and have leftover tumor tissue and some normal blood, bone marrow, or other tissue saved for future research.

Recruiting

More about this study
Decorative Caduceus

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusi...

The Kaplan-Meier method will be used to estimate 3-year FFS along with 80% log-minus-log transformed confidence limits for very low risk (VLR) patients.

Recruiting

More about this study
Decorative Caduceus

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL...

Improvement in 5-year disease-free survival (DFS) with modified Berlin-Frankfurt-Münster (mBFM) chemotherapy without delayed intensification (DI) part 2 but with inotuzumab ozogamicin, versus full mBFM chemotherapy backbone includ...

Recruiting

More about this study
Decorative Caduceus

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Child...

EFS time is calculated from time of randomization to Arms A or B to first episode of disease relapse or progression, second malignancy, or death, or until last contact if no event has occurred.

Recruiting

More about this study
Decorative Caduceus

DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma

o To evaluate the efficacy of difluoromethylornithine (DFMO) as a single agent in preventing relapse in patients with molecular high risk and very high risk medulloblastoma, and relapsed/refractory medulloblastoma based upon the 2...

Recruiting

More about this study
Decorative Caduceus

A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute ...

Summary statistics will be used to characterize the study populations on CHC outcomes. Quantitative data (number of comorbidities) will be summarized using descriptive statistics and correlational techniques. Will use pooled logis...

Recruiting

More about this study
See all clinical trials

Where I see patients (5)

    Fetal surgery firsts

    The first open fetal surgery in the world was performed at UCSF in the early 1980s.

    Share